Sp1281
CASE BY CASE: EXPLORING A PATIENT CASE IN THE TREATMENT OF MODERATE TO SEVERE CD
Date
May 8, 2023
Society: DDW
1) Examine clinical and objective treatment goals 2) Follow the journeys of patients with moderate to severe CD 3) Review the safety and efficacy for patients with moderate to severe CD Sponsored by AbbVie
1) Examine clinical and objective treatment goals 2) Follow the journeys of patients with moderate to severe CD 3) Review the safety and efficacy for patients with moderate to severe CD Sponsored by AbbVie
Presenter
Northwestern Feinberg School of Medicine
Tracks
Related Products
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
PERSISTENCE OF SPLANCHNIC GENE SIGNATURE DEFINES A TUMOR-RESTRAINING FIBROBLAST SUBTYPE IN PANCREATIC CANCER
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
